Humacyte (HUMA) Return on Sales (2020 - 2026)

Humacyte (HUMA) has 5 years of Return on Sales data on file, last reported at 0.62% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.62%, down 13.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.61% (up 167.0% YoY), and the FY2025 annual result was 0.57%, changed N/A from the prior year.
• Return on Sales grew to 0.62% in Q1 2026 per HUMA's latest filing, from 0.72% in the prior quarter.
• Over five years, Return on Sales peaked at 0.35% in Q3 2025 and troughed at 4.84% in Q3 2024.
• A 3-year average of 1.29% and a median of 0.72% in 2025 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2025 and 2026: Return on Sales soared 449 bps in 2025, then dropped 13 bps in 2026.
• A 3-year view of Return on Sales shows it stood at 4.84% in 2024, then soared by 85 bps to 0.72% in 2025, then advanced by 13 bps to 0.62% in 2026.
• Business Quant data shows HUMA's Return on Sales at 0.62% in Q1 2026, 0.72% in Q4 2025, and 0.35% in Q3 2025.